Share Name Share Symbol Market Type Share ISIN Share Description
Hutchison China Meditech LSE:HCM London Ordinary Share KYG4672N1016 ORD USD1
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -12.50p -0.56% 2,205.00p 2,185.00p 2,225.00p 2,205.00p 2,205.00p 2,205.00p 958.00 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 120.9 -7.2 -43.4 - 1,338.51

Hutchison China Meditech (HCM) Latest News

More Hutchison China Meditech News
Hutchison China Meditech Takeover Rumours

Hutchison China Meditech (HCM) Share Charts

1 Year Hutchison China Meditech Chart

1 Year Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Hutchison China Meditech (HCM) Discussions and Chat

Hutchison China Meditech Forums and Chat

Date Time Title Posts
17/1/201711:58(Chi-Med)Hutchinson China Meditech Limited880.00
05/12/201610:52Hutchison China Meditech- CHARTS AND DISCUSSION71.00

Add a New Thread

Hutchison China Meditech (HCM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
10:49:412,220.0090019,980.00O
09:40:002,220.00501,110.00O
09:27:202,220.008177.60O
07:15:112,250.001,09524,637.50O
View all Hutchison China Meditech trades in real-time

Hutchison China Meditech (HCM) Top Chat Posts

DateSubject
23/1/2017
08:20
Hutchison China Meditech Daily Update: Hutchison China Meditech is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchison China Meditech was 2,217.50p.
Hutchison China Meditech has a 4 week average price of 2,251.91p and a 12 week average price of 2,119.39p.
The 1 year high share price is 2,507.50p while the 1 year low share price is currently 1,625p.
There are currently 60,703,323 shares in issue and the average daily traded volume is 3,477 shares. The market capitalisation of Hutchison China Meditech is £1,338,508,272.15.
20/12/2016
12:02
hamsterdam: Yeah, thought it would have moved the share price a little though
07/12/2016
10:11
nerdofsteel: The LSE share price tanked because the NASDAQ IPO (2 x ADR's per AIM Ordinary share) was priced below what was originally expected, presumably because the Institutions taking up the offer wouldn't pay the full price. The effect was the London share price tanked overnight. Now Institutions are starting to buy on NASDAQ, because they can see exactly how valuable the pipeline is and that this Company is unique in the Biotech space eg. it actually generates cash. The bb is quiet because there are very very few Private Investors, most are instutions (it is Mark Slater's largest holding in his growth fund. CK Hutchison hold 60%. IMO most private Investors do not invest because drug development is a very very long term game. However, after 14 years we have our first drugs coming to the market next year and these will be Blockbusters with peak annual sales potential of $100's millions Looking at the sales forecasts, using standard valuations of P/E, P/S, nett margis etc it is my view we will have a mcap in excess of $10bn within the next 5-10 years
04/12/2016
16:41
nerdofsteel: Thanks Steeplejack, I noticed that I have a model which uses a range of criteria to value the Company based on blended Biotech and Pharmaceutical averages of P/E, P/S and nett margins, amongst other metrics. Based in what is a very conservative revenue number of $657m, which assumes Savolitinib and Frquinitinib get BT for certain targets and only achieve 50% of forecast peak sales my valuation figures are:- 2020 Revs $657,000,000 EPS $1.56 P/S 10.92 mcap $5,902,845,408 ADR Price $48.66 Ordinary share price £76.63 (2 x ADR) Moving from 2020 towards 2025 and 2030 the figures become even more interesting. The only thing that may hold back some U.S. Institutional Investors is that there's little if any chance of the Company being taken over, unlike small U.S Biotech's that often get a single drug or a couple of drugs to market then get swallowed up by a major player (Baxalta is a great example)
02/12/2016
10:52
steeplejack: Written up in latest IC -In our view, the high potential of the clinical pipeline makes Chi-Med a very attractive investment proposition and recent share price weakness offers an excellent entry point. Plus, as the group closes in on commercial launch it is likely to grab the attention of more biotech-savvy US investors and that could drive the price up further. Buy.Investors Chronicle 2 Dec
01/8/2016
07:56
miti 1000: Very good news this morning though you would never guess it from the share price.
08/4/2016
09:20
steeplejack: Hopefully that will be the case and the healthcare sector is a bit perkier of late.That said,I find it hard to dismiss the idea that we ,the U.K. holders,got well and truly stuffed by an unexpectedly large placing discount in the USA.We also have to contend with the vagaries of currency moves.Future financing will almost certainly be concentrated in the States.Moreover,it's worth remembering that there's no bid possibility here,this is effectively a close company. The price is a third off its highs.I occasionally consider just kicking the stock into the long grass because it's going to be a long time before the stock hits any new highs.No bid,no yield,it could be heavy going even with reasonable trading updates.When they did that US placing,they behaved like a company majority owned by Hutchinson,they didn't give a fig for existing UK shareholders.The past is the past,it's the future share price I'm interested in.
17/3/2016
07:34
steeplejack: I think that explains the sharp drop in share price some weeks back.The intended pricing of the ADSs must of leaked out.An equivalent London price of £19.42 is a sizeable discount to the existing AIM price.I'd be surprised if we didn't see a few taking a quick profit in the US.Maybe,it was optimistic but I thought (especially given you can get a slug of stock)they might get this placing away at nearer the AIM price ie £22-50 odd.Not to be.I can see them doing the greenshoe,additional placing,in full.Who the hell wouldn't want to go for that at a discount to the London price of getting on for 15%!Nonetheless,they've done the issue in a difficult environment and have a listing in the US which will no doubt prove to be the primary vehicle for any intended fund raising in future years (as it has proven for GWP). "7,500,000 ADSs were sold in the Offering at a price of US$13.50 per ADS, and the offering price is thus equivalent to approximately GBP19.42 per ordinary share (on the basis of an assumed exchange rate as quoted in the preliminary prospectus of GBP1.00 to US$1.39). Each ADS represents one-half of one ordinary share of Chi-Med. The ADSs have been approved for listing on the Nasdaq Global Select Market and are expected to begin trading on March 17, 2016 under the ticker symbol "HCM." Chi-Med's ordinary shares will continue to be traded on the AIM market of the London Stock Exchange following the Offering under the ticker symbol "HCM."
10/11/2015
13:52
hamsterdam: Do us existing shareholders in anyway benefit from the Nasdaq listing? Apart from any rise in the share price on AIM?
03/11/2015
18:48
hamsterdam: Any likelihood HCM decide to delist from the AIM and focus on Nasdaq only? That's my biggest worry as it may hit the share price hard.
03/11/2015
17:42
nerdofsteel: We could via a U.S. Broker, but this will be heavily marketed to Instititional Investors and I think the Company will be pleasantly surprised by the amount of cash that is raised. Smart move, unlimited offer, could raise A LOT of $. The Chairman recently outlined a nice example of a drug calledIbrutinib, developed by Abbvie/Pharmacyclics. That drug alone added $40M to the market cap of Pharmacyclics over a 6 year period before they were acquired by AbbVie. His point is this. Leading Oncology drugs with high efficiacy are worth billions. We have several leading candidates which have taken hundreds of millions of dollars to develop. The only negative I can see is if Clinton wins the election as she is desperate to cap drug prices. The problem for cancer patients is companies will cut back on development of new drugs as a result, as they may not get a return on their investment. Clinton could potentially then effectively be responsible for patients deaths, especially those with rarer forms of cancer. Let's hope we raise a lot of $ on NASDAQ. I also hope we eventually spin off the Innovation Platform into a separate NASDAQ only Company, worth tens of billions of dollars. That will provide a huge reward for those willing to keep this as a long term hold. I'm here for the next 10 years and will look forward to looking back when today's share price will seem very small!
Hutchison China Meditech share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20170123 17:00:28